The SIGLEC14 null allele is associated with Mycobacterium tuberculosis and BCG-induced clinical and immunologic outcomes
Andrew D Graustein, David J Horne, Jerry J Fong, Flavio Schwarz, Heather C Mefford, Glenna J Peterson, Richard D Wells, Munyaradzi Musvosvi, Muki Shey, Willem A Hanekom, Mark Hatherill, Thomas J Scriba, Thuy Thuong Thuong Nguyen, Thi Hoang Mai Nguyen, Maxine Caws, Duc Bang Nguyen, Sarah J Dunstan, Guy E Thwaites, Ajit Varki, Takashi Angata Show all
Tuberculosis | CHURCHILL LIVINGSTONE | Published : 2017
Awarded by NIH
Awarded by Burroughs Wellcome Foundation
We would like to thank the participants in the study. We would also like to thank the immunology and clinical teams at the SATVI research site in Worchester and the Hospital for Tropical Diseases and Pham Ngoc Thac Hospital in Vietnam for obtaining informed consent and collecting and processing blood from the study participants. This research was supported by NIH 5T32HL007287 (ADG), NIH K24 AI089794 (TRH), NIH NO1-AI-70022 (Tuberculosis Research Unit) (TRH, WAH), the Burroughs Wellcome Foundation 1008461 (TRH), and the Dana Foundation (TRH and WAH).